Skip to Main Content

Paper Details

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
Clin Cancer Res
5
2023
BRAF, BRAF-Mutant Melanoma Brain Metastases, BRAFV600E, BRAFV600E genotype, BRV116521, COMBI, Dabrafenib, ECM, MB, MBM, MBMs, Patients, Trametinib, V600 BRAF, dabrafenib, extracranial metastases, melanoma brain metastases, patient, patients, trametinib
Author NameAffiliation
Hussein A TawbiThe University of Texas MD Anderson Cancer Center
Caroline RobertGustave Roussy and Paris Saclay University
Richard A ScolyerMelanoma Institute Australia, The University of Sydney
Richard A ScolyerRoyal Prince Alfred Hospital and NSW Health Pathology
Richard A ScolyerThe University of Sydney
Richard A ScolyerThe University of Sydney
John M KirkwoodThe University of Pittsburgh Medical Center
Georgina V LongMelanoma Institute Australia, The University of Sydney
Georgina V LongRoyal North Shore and Mater Hospitals
Georgina V LongThe University of Sydney
Georgina V LongThe University of Sydney
Michael A DaviesThe University of Texas MD Anderson Cancer Center
Michael A DaviesThe University of Texas MD Anderson Cancer Center
  • 1 - 13

Datasets

Release 1.2